



RenaMed Biologics to Expand Operations to Westborough, MA

Lincoln, RI, March 28th 2006 –RenaMed Biologics, Inc. (RenaMed™) announced today that it has leased a facility in Westborough, Massachusetts to serve as its commercial manufacturing facility for its Renal Bio-Replacement Therapy product for Acute Renal Failure. The company will be relocating its corporate headquarters to Westborough during 2006 and expanding development and manufacturing operations there throughout 2007.

The new facility is in excess of 100,000 sq. ft., and is a multi-use building located on 39 acres in Westborough, Massachusetts. The facility has excellent clean room infrastructure and is well situated to the increasing operational needs of the company. Construction plans are in process and facility renovations are expected to commence in the second quarter of 2006. The first employees will be in Westborough this summer.

“RenaMed Biologics has experienced significant growth over the last few years, in conjunction with very positive phase II clinical data presented at ASN in 2005 and our recently announced partnership with Genzyme Corporation,” said Gregory Phelps, chairman and CEO of RenaMed. “We have outgrown our current facility in Lincoln, RI and need additional space to continue our growth and the development of our Renal Bio-Replacement Therapy. The Westborough facility is uniquely situated to meet our manufacturing needs and provides the overall space we need as we advance to the next stage of our corporate and clinical development.”

RenaMed Biologics, Inc. established its Lincoln, RI operations in 2001 and will continue to operate the Lincoln development and pilot facility in support of its expanding clinical programs. In September 2005 the company entered into a joint development and commercialization program with Genzyme Corporation on its lead product to treat Acute Renal Failure. Under this agreement RenaMed is responsible for establishing the first U.S. manufacturing facility for this product.

About RenaMed Biologics

RenaMed Biologics, Inc. is the leading clinical stage company focused on the development of proprietary Bio-Replacement Therapies for critical disease states involving severely compromised kidney function. The company’s lead product is intended to replace the cellular biologic functions of the kidney that are lost in patients with acute renal failure. The product utilizes physiologically active human renal epithelial cells, administered *ex vivo* in a hollow fiber cartridge. Renal Bio-Replacement Therapy works in conjunction with existing hemofiltration systems and is designed to provide comprehensive kidney function support. Renal Bio-Replacement Therapy is intended to dramatically improve the clinical outcomes and cost of care for patients suffering from ARF. For more information, please visit www.renamedbio.com.

For information contact:

Courtney Harris
Feinstein Kean Healthcare
617-761-6744
courtney.harris@fkhealth.com